Fibrous dysplasia of bone – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:24:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Fibrous dysplasia of bone – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Denosumab for Treating Fibrous Dysplasia/McCune-Albright Syndrome in Adults https://clinicaltrials.eu/trial/study-on-denosumab-for-treating-fibrous-dysplasia-mccune-albright-syndrome-in-adults/ Mon, 03 Aug 2026 10:24:33 +0000 https://clinicaltrials.eu/trial/study-on-denosumab-for-treating-fibrous-dysplasia-mccune-albright-syndrome-in-adults/ This clinical trial is focused on studying the effects of a medication called Denosumab on a condition known as Fibrous Dysplasia/McCune-Albright Syndrome in adults. Fibrous Dysplasia is a rare bone disorder where normal bone is replaced with fibrous tissue, leading to pain and fractures. McCune-Albright Syndrome is a genetic disorder that affects the bones, skin, and several hormone-producing tissues. The purpose of this study is to evaluate how Denosumab affects pain levels in patients with this condition.

Participants in the study will receive Denosumab through subcutaneous injection, which means the medication is injected under the skin. The study will also include a placebo group for comparison. The trial will last for a period of up to 12 months, during which participants will receive two injections over the first six months. The study will assess the impact of Denosumab on pain by comparing pain scores before and after treatment. Additionally, the study will look at other factors such as quality of life, physical activity, and the use of pain medications.

Throughout the study, participants will undergo various assessments, including questionnaires and imaging tests, to monitor changes in their condition. The study aims to provide valuable information on the effectiveness of Denosumab in managing pain and improving the quality of life for individuals with Fibrous Dysplasia/McCune-Albright Syndrome. This research could potentially lead to better treatment options for those affected by this rare condition.

]]>